×

We've got news for you.

Register on BusinessLIVE at no cost to receive newsletters, read exclusive articles & more.
Register now
Covid-19 vaccine maker BioNTech plans to develop targeted antibiotics that could be used against superbugs. Picture: BLOOMBERG
Covid-19 vaccine maker BioNTech plans to develop targeted antibiotics that could be used against superbugs. Picture: BLOOMBERG

Covid-19 vaccine maker BioNTech plans to develop targeted antibiotics that could be used against superbugs, which are bacteria that are resistant to conventional antibiotics. 

The German company is working on a type of synthetic antimicrobial called a ribolysin, which could be deployed against antibiotic-resistant bacteria, chief medical officer Ozlem Tureci said in a presentation to investors on Wednesday. The first patient trials of the platform should begin next year, CEO Ugur Sahin said. 

“The vision is to build a new category of precision antibacterials,” Sahin said. The technology could also allow doctors to target only dangerous bacteria, leaving the body’s natural microbiome intact, he said. 

BioNTech acquired an Austrian biotech, PhagoMed, with precision antibiotics technology last year. Antimicrobial resistance is one of the top 10 global killers, causing more than a million deaths annually, Tureci said. 

Bloomberg News. For more articles like this please visit Bloomberg.com.

subscribe

Would you like to comment on this article?
Register (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.

Commenting is subject to our house rules.